| Clinical data | |
|---|---|
| Other names | BAY 86-5310; SH-T04211C; ZK283197 |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen; Selective ERβ agonist |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| PubChemCID | |
| PubChem SID | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H25FO2 |
| Molar mass | 316.416 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ZK-283197 (also known asBAY 86-5310 orSH-T04211C) is aselective andorally activeERβagonist which was under development byBayer Healthcare AG for the treatment ofvasomotor symptoms.[1][2] It reachedphase IIclinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |